Genomma Lab Internacional SAB de CV (LABB) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.14 M

Shareholding (Jun 2018)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Debt Company with a Debt to Equity ratio (avg) at times

Poor long term growth as Operating profit has grown by an annual rate 7.73% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times
The company has been able to generate a Return on Equity (avg) of 14.48% signifying low profitability per unit of shareholders funds

With ROE of 17.69%, it has a very expensive valuation with a 1.58 Price to Book Value

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

MXN 18,770 Million (Small Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.46

Return on Equity

16.00%

Price to Book

1.71

Revenue and Profits:

Net Sales:

4,676 Million

(Quarterly Results - Jun 2025)

Net Profit:

355 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1942.5%

6 Months

2271.05%

1 Year

1858.7%

2 Years

2152.5%

3 Years

1160.14%

4 Years

1528.56%

5 Years

2258.64%

Genomma Lab Internacional SAB de CV for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.89%

EBIT Growth (5y)

7.73%

EBIT to Interest (avg)

3.31

Debt to EBITDA (avg)

1.32

Net Debt to Equity (avg)

0.44

Sales to Capital Employed (avg)

1.02

Tax Ratio

26.38%

Dividend Payout Ratio

52.17%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

22.18%

ROE (avg)

14.48%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.58

EV to EBIT

5.52

EV to EBITDA

5.02

EV to Capital Employed

1.41

EV to Sales

1.19

PEG Ratio

0.15

Dividend Yield

ROCE (Latest)

25.52%

ROE (Latest)

17.69%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2018

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 6.13% vs -5.56% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -28.81% vs 5.32% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,676.40",
          "val2": "4,406.30",
          "chgp": "6.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,095.70",
          "val2": "1,056.50",
          "chgp": "3.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "257.30",
          "val2": "270.60",
          "chgp": "-4.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "355.00",
          "val2": "498.70",
          "chgp": "-28.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "214.60%",
          "val2": "217.70%",
          "chgp": "-0.31%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.99% vs -2.10% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 92.75% vs -21.90% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18,606.90",
          "val2": "16,467.10",
          "chgp": "12.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,265.00",
          "val2": "3,428.90",
          "chgp": "24.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "887.80",
          "val2": "829.90",
          "chgp": "6.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-8.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,091.10",
          "val2": "1,084.90",
          "chgp": "92.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "209.90%",
          "val2": "194.40%",
          "chgp": "1.55%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

4,676.40

4,406.30

6.13%

Operating Profit (PBDIT) excl Other Income

1,095.70

1,056.50

3.71%

Interest

257.30

270.60

-4.92%

Exceptional Items

0.00

Consolidate Net Profit

355.00

498.70

-28.81%

Operating Profit Margin (Excl OI)

214.60%

217.70%

-0.31%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 6.13% vs -5.56% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -28.81% vs 5.32% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

18,606.90

16,467.10

12.99%

Operating Profit (PBDIT) excl Other Income

4,265.00

3,428.90

24.38%

Interest

887.80

829.90

6.98%

Exceptional Items

0.00

-8.10

100.00%

Consolidate Net Profit

2,091.10

1,084.90

92.75%

Operating Profit Margin (Excl OI)

209.90%

194.40%

1.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 12.99% vs -2.10% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 92.75% vs -21.90% in Dec 2023

All Annual Results

Company CV

About Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV

Pharmaceuticals & Biotechnology

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

Company Coordinates

Company Details

Edificio Samara, Antonio Dovali Jaime no. 70 Piso 2, Colonia Santa Fe, MEXICO, D.F. None : 01210

Tel: 52 55 50810000

http://www.genommalab.com/mx/

Registrar Details